Back to newsroom

JSR Life Sciences to expand KBI Biopharma and Selexis’ biologics manufacturing capabilities in Geneva

Thursday 22 October 2020

A newly expanded, state-of-the-art facility will house both biologics manufacturer KBI Biopharma and cell line developer Selexis. Together, the two companies anticipate creating more than 250 new technical jobs in Geneva.

California-headquartered JSR Life Sciences has announced the expansion of the European gene-to-GMP biologics manufacturing facilities of its affiliate companies KBI Biopharma and Selexis in Geneva. The two companies will occupy 8,700 square meters in the Stellar 32 campus within Geneva’s ZIPLO (Industrial Zone Plan-les-Ouates).

“This expansion is a cornerstone of our European growth strategy, which builds on Selexis’ innovative cell line technologies and KBI’s strong expertise in biologics manufacturing to meet the needs of our clients’ clinical trial requirements,” explained Dirk Lange, President and CEO of KBI Biopharma and CEO of Selexis, in a press release. The co-located operations will help meet the needs of JSR Life Sciences’s European client base.

KBI Biopharma’s new facility, scheduled to be operational by mid-2022, will include two 2,000L single-use cGMP manufacturing trains with process development and analytical testing labs. More than 200 technical positions in development, operations, and quality assurance will be created.

Selexis’ Geneva footprint will increase by 200% once the expanded site is operational by mid-2021. In addition to new standard cell line development suites, the new space will also include two separate cell culture suites to accommodate quarantined client-specific cell lines or client-dedicated cell line spaces.

According to Tim Lowery, President of JSR Life Sciences, “KBI and Selexis will benefit from the extensive biopharma industrial base, advanced technical resources, and specialized education offerings” in Western Switzerland.

Partager sur Twitter Partager sur Facebook Partager sur Whatsapp Partager sur LinkedIn Partager par mail
Back to newsroom

This website uses cookies to improve user experience. More information